CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: October-23-06
Credit Expiration Date: March-09-08


Manju T. Beier, PharmD, FASCP
Senior Partner
Geriatric Consultant Resources LLC
Clinical Associate Professor of Pharmacy
The University of Michigan
Ann Arbor, MI

Tomas L. Griebling, MD, FACS, FGSA
Associate Professor and Vice-Chair
Department of Urology
Faculty Associate
The Landon Center on Aging
Assistant Dean for Student Affairs
The University of Kansas School of Medicine
Kansas City, KS

Credit Hours

Physicians: 1 hour
Pharmacists: 1 hour (0.1 CEU)
Nurses: 1.2 hours (based on a 50-minute hour)
Nurse Practitioners: 1.2 hours (based on a 50-minute hour) (0.3 pharmacology)


Online Presentation

Program Description

This activity was originally presented as a live audioconference series beginning October 23, 2006. If you earned CME or CE credit through the audioconference, you are not eligible to receive credit through this online release.

Urinary incontinence (UI) is highly prevalent among elderly residents in the long-term care, assisted living, and community settings. Diagnosis is sometimes difficult, and treatment is often complicated, especially in residents with multiple comorbidities. A wide range of pharmacologic and nonpharmacologic interventions can be employed to enhance patient care and quality of life. In addition, improved quality of life can be measured by various quality indicators in the long-term care setting. Judicious selection of various interventions is important for improved outcomes.

This program examines the causes of UI in the long-term care setting and its clinical and economic impacts. Diagnostic methods are discussed, and both nonpharmacologic and pharmacologic treatment options are explored. The importance of collaborative practice and team care for best outcomes is a key message of this presentation.

Program Developer/Facilitator


Target Audience

This program has been developed specifically for consultant pharmacists, VA pharmacists, geriatric nurse practitioners, long-term care medical directors, and directors of nursing in long-term care.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss the clinical and economic factors associated with UI in long-term care
  2. Cite the diagnostic criteria for urinary incontinence and current options for assessing and documenting incontinence in long-term care
  3. Evaluate the efficacy, safety, adverse effects, and treatment duration of pharmacotherapy and/or behavior management options
  4. Describe how an interdisciplinary team approach involving physicians, pharmacists, and nurses can optimize care for UI patients in various long-term care settings


Manju T. Beier, PharmD, FASCP, has been a member of the speakers bureau for Novartis Pharmaceuticals Corp., and she has served as a member of the advisory committee for Pfizer Inc.

Tomas L. Griebling, MD, FACS, FGSA, has served as a faculty consultant for the American College of Obstetricians and Gynecologists. He has received research grant support from Pfizer Inc and Astellas Pharma Inc.

It is the policy of ASCP, in accordance with the guidelines set forth by the Accreditation Council for Pharmacy Education, and AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by ASCP and AKH prior to accreditation of the activity.

The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker¹s interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.

This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents including the use of vaginal estrogen for stress incontinence and OAB in women and imipramine for stress or mixed-stress urinary incontinence. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

Pharmacy Continuing Education: The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program (ACPE # 203-999-06-138-H01) was developed by ASCP and is approved for 1.0 Contact Hour (0.1 CEU).

Continuing Medical Education: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Inc. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education: AKH Inc. is accredited by the American Academy of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030803. AKH Inc. designates this educational activity for 1.2 contact hours (based on a 50-minute hour) which includes 0.3 pharmacology contact hour.

Nursing Continuing Education: NADONA/LTC is an approved provider of continuing nursing education by Georgia Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation #1087. This program provides 1.2 contact hours (based on a 50-minute hour) by NADONA/LTC.

To receive continuing education credit, participants must complete a program evaluation and a post-test with a passing grade of 70% or better.

Commercial Support Statements

Supported by an educational grant from Pfizer Inc.


  1. Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
  2. Complete the short survey and click on "done."
  3. The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. This activity will require approximately 60 minutes to complete.
  4. After the program has finished, click on the "Post-test" button. Complete the short survey and click on "done."
  5. Instructions for completing and submitting the post-test and program evaluation are provided on the post-test screen. A credit certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.

Certificate Fee



None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this publication and audioconference are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, the American Society of Consultant Pharmacists, AKH Inc., the National Association of Directors of Nursing Administration in Long-Term Care, or Pfizer Inc. Any medications or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and possible contraindications or risks or without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu